Children with Dravet syndrome face devastating seizures that resist traditional medications, often leading to developmental delays and premature death. This rare genetic epilepsy, caused by mutations in the SCN1A gene encoding sodium channels, has historically been managed through symptom control rather than addressing its underlying cause. The emergence of gene-based interventions represents a fundamental shift from seizure suppression to potentially reversing the disease process itself. Recent advances in adeno-associated virus vectors have enabled researchers to deliver functional copies of SCN1A directly to brain neurons, targeting the root molecular defect. Early clinical data suggests these approaches may restore normal sodium channel function in affected neurons, potentially reducing both seizure frequency and the progressive cognitive decline that characterizes this condition. The therapeutic strategy involves introducing corrective genetic material into specific brain regions most affected by the sodium channel dysfunction. This represents a marked departure from conventional antiepileptic drugs, which often provide incomplete seizure control while carrying significant side effects. The gene therapy approach could theoretically prevent the cascading neurological damage that accumulates over time in Dravet patients. However, several critical limitations temper immediate optimism. The blood-brain barrier remains a formidable challenge for consistent vector delivery, and the long-term safety profile of viral gene therapy in developing brains requires extensive evaluation. Additionally, the optimal timing for intervention remains unclear—whether early treatment can prevent damage or if benefits persist in patients with established neurological complications. While these disease-modifying approaches offer unprecedented hope for families affected by Dravet syndrome, the transition from promising laboratory results to proven clinical benefit will require years of careful study and regulatory review.